Abstract:Background: Inflammatory bowel disease (IBD) is a group of diseases characterized by chronic and recurrent inflammation of the gastrointestinal tract. The etiology of IBD remains multifaceted and poorly understood, resulting in limited treatment options that primarily target disease induction and remission maintenance. Thus, the exploration of novel therapeutic options for IBD among existing medications is advantageous. Mendelian randomization analysis (MR) serves as a valuable tool in investigating the relationship between drugs and diseases. In this study, MR analysis was employed to investigate the potential causal relationship between 23 approved drugs for the treatment of various diseases and IBD. Method: We performed a two-sample MR analysis using publicly available genome-wide association study (GWAS) statistics. The inverse variance weighting (IVW) method was used as the main analysis method, supplemented by the remaining four methods (weighted median, MR Egger regression, simple and weighted models), and Meta-analysis was performed to expand the sample size to obtain a more reliable composite causal effect. Finally, Cochran's Q statistic and the MR-Egger test for directed pleiotropy were applied to determine whether significant heterogeneity or directed pleiotropy existed. Results: In the main MR analysis (IVW), drugs with a negative causal association with the risk of IBD were immunosuppressant {OR (95% CI) = 0.7389 [0.6311-0.8651], p = 0.0046} and diabetes drugs {OR (95% CI) = 0.9266 [0.8876-0.9674], p = 0.0058}. A positive causal association with the risk of IBD was found for salicylic acid and derivatives {OR (95% CI) = 1.2737 [1.0778-1.5053], p = 0.0345}. Negative causal associations with UC risk were identified for immunosuppressants {OR (95% CI) = 0.6660 [0.5133-0.8640], p = 0.0169} and diabetes medications {OR (95% CI) = 0.9020 [0.8508-0.9551], p = 0.0046}; positive causal associations with UC risk were found for β-receptor blockers {OR (95% CI) = 1.1893 [1.0823-1.3070], p = 0.0046}. A negative causal association with the risk of CD was found for immunosuppressants {OR (95% CI) = 0.6957 [0.5803-0.8341], p = 0.0023}. There was no statistically significant association between the remaining 19 drugs and IBD and subtypes. Conclusion: This MR study provides evidence suggesting that immunosuppressants have a mitigating effect on the risk of IBD and demonstrate consistent efficacy in subtypes of ulcerative colitis (UC) and Crohn's disease (CD). Additionally, diabetes medications show potential in reducing the risk of IBD, particularly in cases of UC, while β-blockers may elevate the risk of UC. Conversely, salicylic acid and its derivatives may increase the risk of IBD, although this effect is not consistently observed in the subtypes of the disease. These findings offer new insights into the prevention and management of IBD.

Correlations between genetically predicted lipid-lowering drug targets and inflammatory bowel disease

Lipids, lipid-lowering agents, and inflammatory bowel disease: a Mendelian randomization study

Lipid-lowering drugs and inflammatory bowel disease's risk: a drug-target Mendelian randomization study

Mendelian Randomization As an Approach to Assess Causal Effects of Inflammatory Bowel Disease on Atrial Fibrillation.

Correlation of diet, microbiota and metabolite networks in inflammatory bowel disease

Causal Effects of Blood Lipid Traits on Inflammatory Bowel Diseases: A Mendelian Randomization Study

Integrating plasma proteomics with genome-wide association data to identify novel drug targets for inflammatory bowel disease

Causality of genetically determined blood metabolites on inflammatory bowel disease: a two-sample Mendelian randomization study

Causality Between Gut Microbiota and Inflammatory Bowel Disease: A Bidirectional Mendelian Randomization Study

The Role of Inflammatory Biomarkers in Mediating the Effect of Inflammatory Bowel Disease on nonmalignant Digestive System Diseases: A Multivariable Mendelian Randomized Study

Identification of potential novel targets for treating inflammatory bowel disease using Mendelian randomization analysis

Exploration of the core pathway of inflammatory bowel disease complicated with metabolic fatty liver and two-sample Mendelian randomization study of the causal relationships behind the disease

A Mendelian randomization study on the effects of plasma lipids on irritable bowel syndrome and functional dyspepsia

Identification of key biomarkers for predicting CAD progression in inflammatory bowel disease via machine‐learning and bioinformatics strategies

Mendelian randomization study and mediation analysis about the relation of inflammatory bowel disease and diabetic retinopathy: the further exploration of gut-retina axis

Exploring inflammatory bowel disease therapy targets through druggability genes: a Mendelian randomization study

Association between 23 drugs and inflammatory bowel disease: a two-sample Mendelian randomization study

Causal association of blood cell traits with inflammatory bowel diseases: a Mendelian randomization study

ST2 and CSF‐1 as potential druggable targets of inflammatory bowel diseases: results from two‐sample Mendelian randomization study

Association of serum lipids with inflammatory bowel disease: a systematic review and meta-analysis

Evaluating the causal effect of circulating proteome on the risk of inflammatory bowel disease-related traits using Mendelian randomization